# Orchestra BioMed Holdings, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Orchestra BioMed Holdings, Inc.). ## Overview Orchestra BioMed Holdings, Inc. is a U.S.-based biomedical innovation company focused on developing therapeutic medical device technologies through partnerships with larger medical device companies. Its portfolio includes late-stage product candidates and strategic holdings centered on cardiovascular and surgical applications, with commercialization intended to be advanced through collaborators rather than a fully standalone sales model. ## Products & services • AVIM Therapy for pacemaker-indicated hypertension • Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) • FreeHold intracorporeal organ retractors • Partnership-enabled development and commercialization programs • Strategic holdings in therapeutic device assets - **AVIM Therapy** (0%) — Cardiovascular therapy platform developed for pacemaker-indicated hypertension patients. - **Virtue SAB** (0%) — Sirolimus-based balloon therapy product candidate for vascular intervention. - **FreeHold Surgical Products** (100%) — Intracorporeal organ retractors used in surgical procedures and sold in the U.S. - **Partnership Revenue** (0%) — Collaborative development and commercialization arrangements with strategic partners. - **Strategic Holdings** (0%) — Minority equity, royalty-stream and convertible interests in related device assets. - AVIM Therapy for pacemaker-indicated patients with uncontrolled hypertension - Virtue SAB, a sirolimus-based vascular therapy product candidate - FreeHold intracorporeal organ retractors sold as surgical devices - Development and commercialization collaborations with device partners - Minority equity, royalty-stream and convertible interests in device assets ## Customers The company sells primarily to healthcare providers and medical device partners rather than to consumers. FreeHold products are sold to U.S. surgical customers, while AVIM Therapy and Virtue SAB are developed for commercialization through multinational device partners such as Medtronic and Terumo. Its customer base therefore includes hospitals, surgeons, electrophysiology/cardiology users, and strategic collaboration partners that fund or commercialize the technologies. - **Surgical hospitals and operating rooms** (primary) — Buy FreeHold intracorporeal organ retractors for use in surgical procedures. - **Medical device partners** (primary) — Collaborate on development, regulatory work and commercialization of AVIM Therapy and related assets. - **Cardiology and electrophysiology care settings** (secondary) — Potential end users for AVIM Therapy in pacemaker-indicated hypertension patients. - **Vascular intervention providers** (secondary) — Potential users of Virtue SAB in interventional cardiovascular procedures. - Hospitals and surgical centers buying FreeHold retractors - Surgeons using intracorporeal organ retractors in procedures - Cardiology and electrophysiology providers targeted for AVIM Therapy - Medical device partners funding development and commercialization - Strategic collaborators seeking pipeline assets with lower execution risk ## Geography Orchestra BioMed is headquartered in the United States and its commercial product sales are currently limited to the U.S. FreeHold products are sold only in the United States, while its development partnerships are designed to support global commercialization if products are approved. The company’s exposure is therefore concentrated in U.S. healthcare demand today, with future international reach dependent on partner execution and regulatory approvals. - **United States** (100%) — FreeHold product revenues are currently only sold in the United States. - Headquartered in the United States - FreeHold product sales are currently only in the United States - AVIM Therapy and Virtue SAB are built for broader global commercialization - Partner networks may extend reach beyond the U.S. after approval - Current revenue exposure is concentrated in U.S. healthcare markets ## Strategy The company’s strategy is to advance late-stage therapeutic device candidates through pivotal clinical development while sharing risk and commercialization burden with established device companies. It also seeks value creation through strategic holdings in adjacent assets and through selective product revenue from FreeHold. This model is designed to preserve focus on innovation while leveraging partner infrastructure for regulatory and market access. - **Progress partnered cardiovascular programs** (medium-term) — Partnered development can accelerate regulatory and commercial pathways while limiting standalone build-out needs. - **Expand value from late-stage device pipeline** (medium-term) — Late-stage assets can create value inflection points if clinical and regulatory milestones are achieved. - **Support commercial FreeHold sales** (short-term) — The existing product line provides direct product revenue and operating experience. - Advance AVIM Therapy through partner-supported clinical and regulatory work - Develop Virtue SAB toward pivotal-stage and commercialization milestones - Use established device partners to reduce commercialization burden - Maintain FreeHold as a commercial product line in the U.S. - Create optionality through strategic holdings in related device assets ## Risks The business depends on successful clinical development, regulatory approvals and partner execution, so setbacks in any of those areas can delay or prevent commercialization. It also faces supply-chain concentration, competition from larger device companies, and the risk that product liability or safety issues could limit adoption or trigger regulatory action. Because much of the pipeline is still pre-commercial, the company remains exposed to execution risk and to the uncertainty of converting collaborations into durable revenue. - **Clinical and regulatory failure** [high] — AVIM Therapy and Virtue SAB require successful trials and approvals before broad commercialization. - **Partner dependence** [high] — The business model relies on established device companies for development and commercialization support. - **Supply-chain concentration** [high] — Key components for Virtue SAB are sourced from single manufacturers in China and Singapore. - **Product liability and safety risk** [medium] — Adverse events or labeling changes can reduce market acceptance and trigger legal or regulatory actions. - **Competitive pressure** [medium] — Larger device companies may have broader product lines, stronger distribution and more resources. - Clinical trial or regulatory delays could block product approval - Dependence on Medtronic, Terumo and other partners concentrates execution risk - Single-source suppliers create supply-chain disruption risk - Product safety or liability issues could damage adoption and reputation - Competition from larger device firms may pressure pricing and market access ## Accounting Revenue recognition is judgmental because the company has collaboration arrangements that may be accounted for under both ASC 808 and ASC 606, and product sales are recognized at shipment for FreeHold. Management also highlights estimates tied to combined performance obligations, research and development accruals, and stock-based compensation, which can materially affect period-to-period results. Because the business is still development-heavy, valuation and impairment judgments around strategic holdings and other long-lived or intangible interests may also be important. - **Collaboration revenue recognition** — Can shift revenue between periods and affect comparability - **Point-in-time product revenue** — Quarterly revenue can be affected by shipment timing - **R&D accrual estimates** — Can materially affect operating expenses and liabilities - **Fair value and impairment of strategic holdings** — Can create non-cash gains, losses or impairment charges - Collaboration revenue depends on ASC 808 and ASC 606 assessment - FreeHold product revenue is recognized at shipment, not delivery completion - R&D accruals require estimates of trial and vendor costs - Stock-based compensation affects operating expense and equity dilution - Strategic holdings may require fair value or impairment judgments --- *Last updated: 2026-04-29T04:44:17.747658+00:00*